Title:Dehydrocholesterol Reductase 24 (DHCR24): Medicinal Chemistry,
Pharmacology and Novel Therapeutic Options
Volume: 29
Issue: 23
关键词:
脱氢胆固醇还原酶24,酶抑制剂,去氨甾醇,肝X受体,炎症缓解,非酒精性脂肪性肝炎。
摘要:
During the last decade, the understanding of the biological functions of cholesterol
biosynthesis intermediates has changed significantly. Particularly, the enzyme sterol
dehydrocholesterol reductase 24 (DHCR24) has taken center stage as a potential drug target.
Inhibition of DHCR24 leads to accumulation of the endogenous, biologically active
metabolite cholesta-5,24-dien-3β-ol (desmosterol). Desmosterol is an endogenous agonist
of the liver X receptor (LXR). LXR is a master regulator of lipid metabolism and, as such,
is involved in numerous pathophysiological processes such as inflammation, atherosclerosis,
cancer, diabetes mellitus (DM), multiple sclerosis (MS), nonalcoholic steatohepatitis
(NASH), and the progression of viral infections. Up to now, selective pharmacological
targeting of LXR without activating the sterol-response element binding proteins
(SREBP) and thereby boosting endogenous lipid biosynthesis has not been achieved. In
turn, no selective LXR receptor agonists leveraging its beneficial activation have yet
reached the clinic. Therefore, using potent and selective inhibitors of DHCR24 leading to
an accumulation of endogenous desmosterol is a promising alternative strategy for the selective
activation of LXR.
Here we summarize the present landscape of novel lead structures for targeting DHCR24,
covering steroidal enzyme inhibitors (e.g., 20,25-diazacholesterol, SH42) as well as nonsteroidal
scaffolds (e.g., amiodarone, triparanol). Further, we explain the molecular mechanisms
of DHCR24 inhibition/LXR activation, discuss possible therapeutic applications,
and underpin why DHCR24 is an upcoming promising drug target.